Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Farhad Ravandi; Robert J. Kreitman; Enrico Tiacci; Leslie Andritsos; Versha Banerji; Jacqueline C. Barrientos; Seema A. Bhat; James S. Blachly; Alessandro Broccoli; Timothy Call; Dai Chihara; Claire Dearden; Judit Demeter; Sasha Dietrich; Monica Else; Narendranath Epperla; Brunangelo Falini; Francesco Forconi; Douglas E. Gladstone; Alessandro Gozzetti; Sunil Iyengar; James B. Johnston; Jeffrey Jorgensen; Gunnar Juliusson; Francesco Lauria; Gerard Lozanski; Sameer A. Parikh; Jae H. Park; Aaron Polliack; Graeme Quest; Tadeusz Robak; Kerry A. Rogers; Alan Saven; John F. Seymour; Tamar Tadmor; Martin S. Tallman; Constantine S. Tam; Philip A. Thompson; Xavier Troussard; Clive S. Zent; Thorsten Zenz; Pier Luigi Zinzani; Bernhard Wörmann; Kanti Rai; Michael Grever

doi:10.1038/s41408-022-00760-z

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Farhad Ravandi^*, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro GozzettiSunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.

Original language	English (US)
Article number	165
Journal	Blood cancer journal
Volume	12
Issue number	12
DOIs	https://doi.org/10.1038/s41408-022-00760-z
State	Published - Dec 2022

Funding

This work was supported by funding and support from the Hairy Cell Leukemia Foundation. The authors would like to acknowledge Anna Lambertson for the editorial support provided.

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-022-00760-z

Cite this

Ravandi, F., Kreitman, R. J., Tiacci, E., Andritsos, L., Banerji, V., Barrientos, J. C., Bhat, S. A., Blachly, J. S., Broccoli, A., Call, T., Chihara, D., Dearden, C., Demeter, J., Dietrich, S., Else, M., Epperla, N., Falini, B., Forconi, F., Gladstone, D. E., ... Grever, M. (2022). Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal, 12(12), Article 165. https://doi.org/10.1038/s41408-022-00760-z

@article{00fd8a2e250d448f975e402eab5beaa7,

title = "Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia",

abstract = "A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.",

author = "Farhad Ravandi and Kreitman, {Robert J.} and Enrico Tiacci and Leslie Andritsos and Versha Banerji and Barrientos, {Jacqueline C.} and Bhat, {Seema A.} and Blachly, {James S.} and Alessandro Broccoli and Timothy Call and Dai Chihara and Claire Dearden and Judit Demeter and Sasha Dietrich and Monica Else and Narendranath Epperla and Brunangelo Falini and Francesco Forconi and Gladstone, {Douglas E.} and Alessandro Gozzetti and Sunil Iyengar and Johnston, {James B.} and Jeffrey Jorgensen and Gunnar Juliusson and Francesco Lauria and Gerard Lozanski and Parikh, {Sameer A.} and Park, {Jae H.} and Aaron Polliack and Graeme Quest and Tadeusz Robak and Rogers, {Kerry A.} and Alan Saven and Seymour, {John F.} and Tamar Tadmor and Tallman, {Martin S.} and Tam, {Constantine S.} and Thompson, {Philip A.} and Xavier Troussard and Zent, {Clive S.} and Thorsten Zenz and Zinzani, {Pier Luigi} and Bernhard W{\"o}rmann and Kanti Rai and Michael Grever",

note = "Funding Information: This work was supported by funding and support from the Hairy Cell Leukemia Foundation. The authors would like to acknowledge Anna Lambertson for the editorial support provided. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41408-022-00760-z",

language = "English (US)",

volume = "12",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "12",

}

Ravandi, F, Kreitman, RJ, Tiacci, E, Andritsos, L, Banerji, V, Barrientos, JC, Bhat, SA, Blachly, JS, Broccoli, A, Call, T, Chihara, D, Dearden, C, Demeter, J, Dietrich, S, Else, M, Epperla, N, Falini, B, Forconi, F, Gladstone, DE, Gozzetti, A, Iyengar, S, Johnston, JB, Jorgensen, J, Juliusson, G, Lauria, F, Lozanski, G, Parikh, SA, Park, JH, Polliack, A, Quest, G, Robak, T, Rogers, KA, Saven, A, Seymour, JF, Tadmor, T, Tallman, MS, Tam, CS, Thompson, PA, Troussard, X, Zent, CS, Zenz, T, Zinzani, PL, Wörmann, B, Rai, K & Grever, M 2022, 'Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia', Blood cancer journal, vol. 12, no. 12, 165. https://doi.org/10.1038/s41408-022-00760-z

TY - JOUR

T1 - Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

AU - Ravandi, Farhad

AU - Kreitman, Robert J.

AU - Tiacci, Enrico

AU - Andritsos, Leslie

AU - Banerji, Versha

AU - Barrientos, Jacqueline C.

AU - Bhat, Seema A.

AU - Blachly, James S.

AU - Broccoli, Alessandro

AU - Call, Timothy

AU - Chihara, Dai

AU - Dearden, Claire

AU - Demeter, Judit

AU - Dietrich, Sasha

AU - Else, Monica

AU - Epperla, Narendranath

AU - Falini, Brunangelo

AU - Forconi, Francesco

AU - Gladstone, Douglas E.

AU - Gozzetti, Alessandro

AU - Iyengar, Sunil

AU - Johnston, James B.

AU - Jorgensen, Jeffrey

AU - Juliusson, Gunnar

AU - Lauria, Francesco

AU - Lozanski, Gerard

AU - Parikh, Sameer A.

AU - Park, Jae H.

AU - Polliack, Aaron

AU - Quest, Graeme

AU - Robak, Tadeusz

AU - Rogers, Kerry A.

AU - Saven, Alan

AU - Seymour, John F.

AU - Tadmor, Tamar

AU - Tallman, Martin S.

AU - Tam, Constantine S.

AU - Thompson, Philip A.

AU - Troussard, Xavier

AU - Zent, Clive S.

AU - Zenz, Thorsten

AU - Zinzani, Pier Luigi

AU - Wörmann, Bernhard

AU - Rai, Kanti

AU - Grever, Michael

N1 - Funding Information: This work was supported by funding and support from the Hairy Cell Leukemia Foundation. The authors would like to acknowledge Anna Lambertson for the editorial support provided. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.

AB - A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.

UR - http://www.scopus.com/inward/record.url?scp=85143667485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85143667485&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00760-z

DO - 10.1038/s41408-022-00760-z

M3 - Review article

C2 - 36509740

AN - SCOPUS:85143667485

SN - 2044-5385

VL - 12

JO - Blood cancer journal

JF - Blood cancer journal

IS - 12

M1 - 165

ER -

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this